Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Karyopharm Files Supplemental New Drug Application with FDA for XPOVIO® (Selinexor) in Combination with Ruxolitinib for the Treatment of Myelofibrosis

with ruxolitinib compared to placebo plus ruxolitinib in JAKi-naïve myelofibrosis patients with platelet counts >100 x 109/L (N=353). Patients were randomized 2-to-1 to the selinexor arm. The co-primary endpoints for this trial are spleen volume...

Choose Health Launches Comprehensive At-Home Liver Function Test Featuring 20+ Biomarkers and Clinical Risk Scores

Its trajectory can often be changed: AASLD guidance indicates 3 to 5% weight loss can improve steatosis, with above 10% needed to improve steatohepatitis and fibrosis What does the Choose Health Comprehensive Liver Function Test measure? The test...

Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

Abbott the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) authorization of its Libre Duo 10 Day system, the world's first dual glucose‑ketone sensing technology. The new biowearable is designed to alert people...

U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

for people with HER2+ advanced GEA. Ziihera is now the first and only bispecific HER2-targeted antibody combined with a PD-1 inhibitor and chemotherapy approved for all HER2+ advanced GEA patients, regardless of PD-L1 status, establishing a new...

European Commission Approves DAYBU® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms Associated with Rett Syndrome in the European Union

About Rett Syndrome Rett syndrome is a rare, complex, neurodevelopmental disorder and occurs in approximately one of every 10,000 to 15,000 female births worldwide.1-3 A child with Rett syndrome generally exhibits an early period of apparently...

Upsher-Smith Expands Neurology Portfolio with the Launch of Glatiramer Acetate Injection

Upsher-Smith Laboratories, LLC a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX), announced the recent launch of Glatiramer Acetate Injection in 20 mg/mL and 40 mg/mL strengths, adding to the Company's portfolio of complex...

Dunbar Pharma Brings First Plant-Derived Dronabinol API to the UK Market Through IPS Pharma

precision for individualised prescribing. CBPMs manufactured with WaterClear THC™ are supplied in 5 mg and 10 mg capsules, a 25 mg/mL oral dose spray, and a 25 mg/mL oily dropper solution. These may be prescribed where clinically appropriate under...

Former DePuy Synthes U.S. President Joins Peptilogics Board

Tim Czartoski, orthopedic executive and former president of DePuy Synthes U.S. and most recently president of U.S. Surgical and Global R&D at Enovis, has joined the Peptilogics board of directors. His background in leading large orthopedic device...

PanTRKare™ Is Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)

NMPA granted approval to Geneseeq's PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The approval...

Bruker and Atinary Technologies Join Forces to Accelerate the Future of Self-Driving Laboratories

About Atinary Technologies Atinary Technologies is the pioneer of Self-Driving Labs®, a term its founders coined in 2017. Atinary's mission is to augment humans with AI and robotics to drive a Moore's Law of Discovery, exponentially accelerating...

Neurolief Advances Veteran Mental Health and Migraine Care With New VA Contract for Prescription Neuromodulation

often classified as having treatment-resistant depression, comprise approximately 30% of the overall MDD population1 and represent a significant unmet medical need. "Too many people I treat have carried depression for years, moving from one...

AVANTIK Appoints Jeffrey Waldman as Chief Executive Officer

two decades of healthcare leadership experience and a strong track record of building high-performing businesses. During a 19-year career at Henry Schein, he spearheaded strategic, operational and commercial initiatives across key businesses. As...

BioVigil Reaches 1 Billion Hand Hygiene Opportunities, Marking a Major Milestone in Patient Safety and Infection Prevention

the market leader in automated hand hygiene and infection prevention technology, announced that it has recorded more than 1 billion hand hygiene opportunities (HHOs) since the company’s founding in 2012. This milestone reflects the ongoing...

Bruker Announces Majority Stake in MIMETAS to Accelerate Drug Discovery and Development Using Human Physiology-Relevant Models

Bruker Corporation announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment expands Bruker’s post-genomic solutions...

U.S. FDA Accepts sBLA for ENFLONSIA™ to Expand RSV Indication to High-Risk Children Under Two

during their second RSV season. Both the U.S. and EU applications are supported by data from the Phase 3 SMART trial (MK-1654-007), which were presented at RSVVW’26, the 9th conference of the Respiratory Syncytial Virus Foundation (ReSViNET), in...

Takeda's ORZEYFUL™ Receives U.S. FDA Approval for Narcolepsy Type 1

(FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can...

Why the Pharmacy System Rewards the Wrong Results: It Is Working as Designed

Grows as Drug Spending Rises National prescription drug spending increased 7.9% to $467 billion in 2024 after growing 10.8% the previous year, according to the Centers for Medicare & Medicaid Services (CMS). Retail prescription drug spending is...

Triquetra Health Launched BioActive Vitamin B1™—the First Complete B1 Activation System with a 600 mg Research-Matched Dose and Full Cofactor Support

a clinical-grade supplement company specializing in evidence-based formulation, announced the launch of BioActive Vitamin B1™ Clinical Strength, a complete B1 activation system delivering 600mg benfotiamine at the research-matched dose alongside a...

Dallas-Based Microbiome Brand resbiotic® Comes Home to Texas with Launch at H-E-B

more than digestion alone. resB specifically targets the Gut-Lung Axis, using resbiotic's proprietary probiotic strains (RSB11®, RSB12®, and RSB13®) to support respiratory health from the inside out. Few places understand the need for daily...

US Capital Global Securities Announces $20 Million Offering for Thplasma to Invest in the Future of Plasma Therapeutics

to present eligible investors with the opportunity to participate in a $20 million financing for Thplasma comprising a $15 million equity investment and a $5 million venture debt facility. Thplasma is a U.S.-based pharmaceutical company operating...